POTTER MYRTLE S sold $204K of GH

POTTER MYRTLE S sold 1,556 shares of Guardant Health, Inc. (GH) at $131.16 ($0.20M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · POTTER MYRTLE S
Published Jun 23, 2026, 9:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosure updates the insider’s post-transaction holdings but does not introduce new company fundamentals.

02

Market read

A director’s scheduled sale under 10b5-1 is generally low-signal for price action absent other catalysts.

03

What to watch

Traders may over-weight insider sales; without accompanying buys, guidance changes, or clinical/regulatory updates, the signal is typically weak.

Relevance 3/10Novelty 3/10Timing: Form 4 filed 2026-06-23 after-hours/late session disclosure

Background

This is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health director POTTER MYRTLE S sold 1,556 shares on 2026-06-22 for $131.16/share under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other new company-specific catalysts.

Evidence & confidence

The filing is a standard director sale with a stated 10b5-1 plan, and the article provides no new operational, financial, or regulatory development for GH.

Market effects

No meaningful read-across to biotech/diagnostics sector fundamentals from a single director sale.

None.

None.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.

Key entities

  • Guardant Health, Inc.

    Subject of the Form 4 insider transaction disclosure (GH).

  • POTTER MYRTLE S

    Director who executed an open-market sale under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.